LATAM Pain Management Drugs Market Updates 2024 : Growth Drivers and Challenges 2019-2027
LATAM pain management drugs market is projected to reach $3,383.20 million by 2027, registering a CAGR of 3.5% from 2020 to 2027.
WILMINGTON, DELAWARE , UNITED STATES, July 19, 2024 /EINPresswire.com/ -- The growth of the LATAM pain management drugs market1 is driven by several factors, including an increase in the incidence of chronic diseases, a favorable regulatory environment, and a rising geriatric population. However, market expansion is hindered by the availability of alternative therapies, issues with drug misuse, and the expiration of patents on key prescription medications. On the positive side, advancements in drug development and the untapped potential in developing countries present promising opportunities for future market growth.
The Latin American (LATAM) Pain Management Drugs market is projected to grow significantly over the next few years. The market, valued at $2,683.82 million in 2019, is expected to reach $3,383.20 million by 2027, growing at a compound annual growth rate (CAGR) of 3.5% from 2020 to 2027โโ.
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/A07588
Key Market Segments
By Drug Class:
Opioids: The largest segment due to their high efficiency in relieving chronic painโ (Allied Market Research)โโ (EIN Presswire)โ.
NSAIDs: Commonly used for their anti-inflammatory propertiesโ (Valuates)โ.
Anesthetics, Anticonvulsants, Antimigraine agents, Antidepressants, Non-narcotic analgesics: Other notable segments showing varied growth rates.
By Indication:
Neuropathic Pain and Chronic Back Pain: Significant contributors to market revenueโ (Allied Market Research)โ.
Cancer Pain: Expected to have the highest growth rate due to the increasing prevalence of cancerโ (Valuates)โ.
Postoperative Pain, Arthritic Pain, Migraine, Fibromyalgia: Other important indications driving market growthโ (Allied Market Research)โโ (Valuates)โ.
Regional Insights
Brazil: Holds the majority market share, attributed to a large aging population and favorable regulatory conditionsโ (Allied Market Research)โ.
Argentina: Predicted to have the highest growth rate due to an increasing patient population and healthcare expenditureโ (Allied Market Research)โโ (Allied Market Research)โ.
Other Countries: Colombia, Peru, Chile, Ecuador, and Panama are also significant marketsโ (Valuates)โ.
Market Drivers
Increasing Prevalence of Chronic Diseases: Such as cancer, diabetic neuropathy, and osteoarthritisโ.
Rising Number of Surgical Procedures: Leading to a higher demand for postoperative pain managementโ.
Growing Geriatric Population: Elderly individuals are more prone to chronic pain conditionsโโ.
Advancements in Treatment Options: Including both pharmacological and non-pharmacological therapiesโโ.
Challenges
Patent Expiration of Key Drugs: Impacting market revenue as generic alternatives become availableโโ.
Availability of Alternative Therapies: Such as acupuncture and massage, which may reduce dependence on pharmaceutical solutionsโโ.
In summary, the LATAM Pain Management Drugs market is poised for growth, driven by increasing chronic disease prevalence, rising surgical procedures, and an expanding elderly population. However, it faces challenges such as patent expirations and the availability of alternative therapiesโ.
๐๐จ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ฒ๐ข๐ง๐ https://www.alliedmarketresearch.com/purchase-enquiry/A07588
The LATAM pain management drugs market is analyzed across several regions such as Brazil, Argentina, Colombia, Peru, Chile, Ecuador, Panama, and Rest of Latin America. The market across Brazil held the lionโs share in 2019, accounting for nearly half of the market. However, the market across Argentina is expected to register the highest CAGR of 4.3% from 2020 to 2027.
The LATAM pain management drugs market report includes an in-depth analysis of the major market players such as Novartis AG, Eli Lilly & Company, Abbott Laboratories, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc.
๐๐๐ฒ ๐๐๐ง๐๐๐ข๐ญ๐ฌ ๐
๐จ๐ซ ๐๐ญ๐๐ค๐๐ก๐จ๐ฅ๐๐๐ซ๐ฌ
The study provides an in-depth analysis of the LATAM pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
The LATAM pain management drugs market forecast is studied from 2020 to 2027
Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
Key market players and their strategies have been analysed to understand the competitive outlook of the LATAM pain management drugs market.
๐๐๐ฒ ๐
๐ข๐ง๐๐ข๐ง๐ ๐ฌ ๐๐ ๐๐ก๐ ๐๐ญ๐ฎ๐๐ฒ
By drug class, the opioids segment generated $683 million of the LATAM pain management drug market in 2019.
By indication, the cancer pain segment is anticipated to grow with the highest CAGR throughout the forecast period.
By country, Brazil is accounted for the largest market in LATAM during the forecast period.
๐๐ญ๐ก๐๐ซ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐ข๐ง ๐๐ข๐๐ ๐๐๐ข๐๐ง๐๐ ๐๐จ๐ฆ๐๐ข๐ง
๐๐จ๐ฏ๐ข๐ง๐ ๐๐๐ฌ๐ญ๐ข๐ญ๐ข๐ฌ ๐๐๐ซ๐ค๐๐ญ https://www.alliedmarketresearch.com/bovine-mastitis-market-A17539
๐๐จ๐๐ญ๐ ๐๐ฅ ๐๐๐ฉ๐ฌ๐ฎ๐ฅ๐๐ฌ ๐๐๐ซ๐ค๐๐ญ https://www.alliedmarketresearch.com/softgel-capsules-market-A16306
David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X
1 https://www.alliedmarketresearch.com/latam-pain-management-drugs-market-A07588
2 https://www.globenewswire.com/en/news-release/2020/11/25/2133924/0/en/LATAM-Pain-Management-Drugs-Market-to-Garner-3-38-Billion-by-2027-Allied-Market-Research.html
3 https://www.alliedmarketresearch.com/softgel-capsules-market-A16306
![](https://www.einpresswire.com/tracking/article.gif?t=4&a=Mc1WuS6dICXBk0Fo&i=JTbmFCDxpii2ug9V)